Vitamin D and Chronic Kidney Disease
DOI:
https://doi.org/10.22141/2307-1257.0.2.2012.176613Keywords:
vitamin D, chronic kidney diseaseAbstract
The results of 25(ОН)D3 level determination in blood serum of 45 patients with I–V stage chronic kidney disease are described in this article. It is shown that sufficient 25(ОН)D3 level is registered with 6.7 % of patients, vitamin D deficiency — in 24.4 % of patients. Vitamin D (< 50 nM/l) deficiency took detected in 68.9 % of patients. High direct correlation (r = 0.76) was found between the levels of 25(ОН)D3 and total protein. Average inverse power connection (r = –0.35) was determined between the levels of PTH and 25(ОН)D3 in the serum, and the level of urinary protein excretion and 25(ОН)D3 (r = –0.46).Downloads
References
Михайлова Н.А. Селективный активатор витамин-Дрецепторов парикальцитол и его место в лечении хронической болезни почек. Обзор литературы // Лечащий врач. — 2011. — № 2. — С. 82-88.
Николаев А.Ю., Милованов Ю.С. Лечение почечной недостаточности. — М.: Медицинское информационное агентство, 2011. — 592 с.
Alvarez J.A., Law S., Coakley K. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, doubleblind, placebocontrolled trial // Am. J. Clin. Nutr. — 2012. — 96(3). — P. 672-679.
Alvarez J., Wasse H., Tangpriche V. Vitamin D supplementation in predialysis chronic kidney disease: A systematic review // Dermatoendocrinol. — 2012. — 4(2). — P. 118-127.
Brancaccio D., Cozzolino M., Cannella G. et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO Survey on treatment and mortality // Blood. Purif. — 2011. — № 2. — P. 124-132.
Damasiewiez H., Magliano D., Doly R. 25-hydroxyvitamin D levels and chronic kidney disease in the Aus Diab (Australian Diabets, Obesity and Lifestyle) study // BMC Nephrol. — 2012. — Abstract Jul.
De Zeeuw D., Agarwal R., Amdahl M. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial // Lancet. — 2010. — 376(9752). — С. 1543-1551.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD) // Kidney International. — 2009. — 76(Suppl. 113). — P. 1-130.
Mazzaferro S., Brancaccio D., Messa P. et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey // J. Nephrol. — 2011. — № 24(2). — P. 225-235.
Navaneethan S.D., Schold S.D., Arrigain S., Jolly S.E. et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysisdependent CKD // Am. J. Kid. Dys. — 2011. — 58(4).— P. 536-543.
Pilz S., Iodices S., Zittermann A., Grant W.P., Giandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies // Am. J. Kid. Dis. — 2011. — 58(3). — P. 374-382.
Urena-Torres P., Metzger M., Haymann J.P., Karra S.A. et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD // Am. J. Kid. Dis. — 2011. — 58(4). — P. 544553.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 S.V. Kushnirenko, L.P. Gorbatova, O.M. Bogoliy
This work is licensed under a Creative Commons Attribution 4.0 International License.